Establishment Labs Holdings Inc. - 10-Q Summary (Q3 2025)
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Establishment Labs Holdings Inc. is a global medical device company manufacturing and marketing silicone gel-filled breast implants (Motiva Implants) and related aesthetic technologies. The company operates manufacturing facilities in Costa Rica and sells products in over 90 countries. Following FDA approval in September 2024, the company has been actively commercializing its products in the United States.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $53.8 million | $40.2 million | $146.5 million | $121.5 million |
| Gross Profit | $37.7 million | $25.7 million | $100.8 million | $79.0 million |
| Gross Margin | 70.1% | 63.9% | 68.8% | 65.0% |
| Net Loss | $(11.1) million | $(16.7) million | $(48.4) million | $(50.1) million |
| Loss Per Share (Basic/Diluted) | $(0.38) | $(0.59) | $(1.64) | $(1.80) |
| Cash and Equivalents (End of Period) | $70.6 million (as of Sept 30, 2025) | |||
| Total Debt (Principal) | $246.4 million (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 33.8% in Q3 and 20.6% YTD compared to the prior year. This was driven primarily by North American sales following FDA approval, alongside growth in Latin America and Asia-Pacific.
- Margin Expansion: Gross margin improved to 70.1% in Q3 (from 63.9% in Q3 2024) due to higher selling prices in the U.S. market.
- Operating Expenses: SG&A expenses increased significantly ($37.2M in Q3 vs. $34.1M in Q3 2024) due to higher commissions, consulting fees, and shipping costs associated with U.S. expansion. R&D expenses remained relatively flat.
- Debt Financing: In September 2025, the company drew down the final $25 million tranche (Tranche D) of its Oaktree Credit Agreement, bringing total outstanding principal to $246.4 million (including accrued interest).
- Foreign Currency: The company recorded a $7.4 million foreign currency transaction gain YTD 2025, compared to a $3.6 million loss in the prior year period.
Guidance, Outlook, and Risks
- Outlook: Management expects operating expenses to increase in 2025 due to commercial and operational activities in the U.S. following FDA approval. Demand remains sensitive to macroeconomic conditions, including inflation and consumer spending power.
- Liquidity: The company believes its cash resources ($70.6M) and anticipated cash flow will satisfy liquidity requirements for at least the next 12 months. It maintains a $10 million inventory funding facility for raw materials.
- Key Risks:
- Single-Source Supplier: Reliance on Avantor as the sole supplier of medical-grade silicone.
- Regulatory: Ongoing requirements for post-market studies (PAS) in the U.S. and potential regulatory changes.
- Market Perception: Industry-wide scrutiny regarding breast implant safety (e.g., BIA-ALCL) could impact demand.
- Profitability: The company has an accumulated deficit of $493.1 million and does not expect to be profitable in 2025.
Investor Verification Checklist
- U.S. Sales Trajectory: Verify the sustainability of the 33.8% Q3 revenue growth driven by U.S. market penetration post-FDA approval.
- Debt Covenants: Confirm compliance with the minimum liquidity covenant (raised to $30 million in Sept 2025) and gross sales thresholds under the Oaktree Credit Agreement.
- Supplier Concentration: Assess the risk mitigation strategies regarding the sole-source dependency on Avantor for silicone raw materials.
- Cash Burn Rate: Monitor the net cash used in operating activities ($50.7M YTD) against the current cash balance to evaluate runway.
- Post-Market Study Costs: Review the estimated $4.0M–$5.0M cost for the required 10-year Post-Approval Study (PAS) and its impact on future R&D budgets.